Invictus MD Strategies (Invictus MD Strategies) GF Value : $0.00 (As of May. 16, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-16), Invictus MD Strategies's share price is $0.0001. Invictus MD Strategies's GF Value is $0.00. Therefore, Invictus MD Strategies's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Invictus MD Strategies is Not Valued.

Invictus MD Strategies (OTCPK:IVITF) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Invictus MD Strategies's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0001	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invictus MD Strategies GF Value Related Terms

Thank you for viewing the detailed overview of Invictus MD Strategies's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Invictus MD Strategies (Invictus MD Strategies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1

Website

http://www.invictus-md.com

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.